Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Biomarkers, 2021
    Use of Neuronal Exosomes to Predict Parkinson’s Disease

    Study Rationale:
    In Parkinson’s disease (PD), the build-up of alpha-synuclein inside nerve cells leads to formation of abnormal clumps and death of dopamine-producing cells and other neurons. By the...

  • Therapeutic Pipeline Program, 2021
    Development of Compounds that Destroy Alpha-Synuclein Aggregates for the Treatment of Parkinson’s Disease

    Study Rationale:
    Multiple lines of evidence indicate that alpha-synuclein forms aggregates similar to those adopted by infectious prion proteins, and that these toxic clusters are responsible for the...

  • Therapeutic Pipeline Program, 2021
    Directed Evolution of Tailor-Made Molecular Chaperones

    Study Rationale:
    For cells to operate properly, the proteins they produce must fold properly and maintain the correct three-dimensional structure. This process relies on a special class of proteins...

  • Therapeutic Pipeline Program, 2021
    Evaluation of a Drug that Removes Excess Iron from the Brain as a Treatment for Parkinson’s Disease

    Study Rationale:
    In Parkinson’s disease (PD), the death of cells in brain regions that control movement causes motor symptoms. Brain imaging studies show that iron builds up in these areas, damaging...

  • Priority Biology, 2021
    LRRK2 Regulation of Melanoma Progression

    Study Rationale:
    People with Parkinson's disease (PD) are more likely to develop melanoma, and people with melanoma are more likely to develop PD than the general population. Additionally, melanoma...

  • Therapeutic Pipeline Program, 2021
    RNA Targeting Small Molecules as Therapeutics for Parkinson's

    Study Rationale:    
    Abnormal clumping of the protein alpha-synuclein is a hallmark of Parkinson's disease (PD) and a likely cause of neurodegeneration and, ultimately, symptoms. One of the causes...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.